DUBLIN--(BUSINESS WIRE)--The "Asia-Pacific Companion Diagnostics Market 2022-2028" report has been added to ResearchAndMarkets.com's offering.
The publisher's research report suggests that the Asia-Pacific companion diagnostics market is anticipated to showcase a CAGR of 13.10% during the forecasted years 2022-2028. China, India, Australia & New Zealand, Japan, ASEAN countries, South Korea, and Rest of Asia-Pacific are considered in the region.
India is considered a major emerging genomics market, with oncologists accepting biomarker-based tests. The rising middle-class healthcare facilities and skilled practitioners have driven the expansion of clinical diagnostics in the country. Besides this, government hospitals like AIIMS and NIMHANS are striving to identify new disease genes and biomarkers.
Therefore, these factors are expected to fuel the development of the companion diagnostics market across India over the forecast period.
In South Korea, the public healthcare system is offered to all citizens through the National Health Insurance Corporation under the Ministry of Health and Wellness.
As per WHO, the Ministry is in charge of policies and supervision of the healthcare systems. In this regard, the Health Insurance Review Agency reviews medical charges, evaluating the overall healthcare system. The overall development of the healthcare system supports the demand for companion diagnostics tests, driving the South Korean market's growth.
Companies Mentioned
- Abbott Laboratories
- Almac Group
- Arup Laboratories
- Biocartis
- Biomerieux
- Danaher Corporation
- GE Healthcare
- Genomic Health
- Illumina Inc
- Myriad Genetics
- Qiagen
- Roche Diagnostics
- Sysmex Corporation
- Thermo Fisher Scientific
- Agilent
Key Topics Covered:
1. Asia-Pacific Companion Diagnostics Market - Summary
2. Industry Outlook
2.1. Impact of Covid-19 on the Companion Diagnostics Market
2.2. Key Insights
2.2.1. Commercial Success of Precision Medicine Treatment
2.2.2. Adoption of Predictive Biomarkers
2.2.3. Fusion of Computer Science and Biology
2.3. Porter'S Five Forces Analysis
2.3.1. Threat of New Entrants
2.3.2. Threat of Substitutes
2.3.3. Bargaining Power of Buyers
2.3.4. Bargaining Power of Suppliers
2.3.5. Threat of Competitive Rivalry
2.4. Key Buying Impact Analysis
2.4.1. Cost
2.4.2. Availability
2.4.3. Sensitivity & Specificity
2.4.4. Efficacy
2.5. Market Attractiveness Index
2.6. Vendor Scorecard
2.7. Industry Components
2.8. Regulatory Framework
2.9. Key Market Strategies
2.9.1. Acquisitions
2.9.2. Product Launches
2.9.3. Contracts & Agreements
2.10. Market Drivers
2.10.1. Increase in Incidence of Medication Reactions
2.10.2. Increasing Prevalence of Cancer Cases and Fatalities
2.10.3. Rising Prevalence of Precision Medicines
2.11. Market Challenges
2.11.1. Weak Reimbursement Framework
2.11.2. Common Cases of Leakage in Oncology Companion Diagnostics
2.12. Market Opportunity
2.12.1. Ongoing Research and Investments in Next Generation Gene-Sequencing
3. Asia-Pacific Companion Diagnostics Market Outlook - by Mechanism
3.1. In-Situ Hybridization
3.2. Polymerase Chain Reaction
3.3. Immunohistochemistry
3.4. Next Generation Sequencing
3.5. Other Mechanisms
4. Asia-Pacific Companion Diagnostics Market Outlook - by Indicator
4.1. Oncology
4.2. Neurology
4.3. Infectious Diseases
4.4. Other Indicators
5. Asia-Pacific Companion Diagnostics Market Outlook - by Consumer
5.1. Pharmaceutical and Biopharmaceutical Companies
5.2. Reference Laboratories
5.3. Other Consumers
6. Asia-Pacific Companion Diagnostics Market Outlook - by Commodity
6.1. Assay Kits and Reagents
6.2. Software and Services
7. Asia-Pacific Companion Diagnostics Market - Country Outlook
7.1. China
7.2. Japan
7.3. India
7.4. South Korea
7.5. Asean Countries
7.6. Australia & New Zealand
7.7. Rest of Asia-Pacific
8. Competitive Landscape
9. Research Methodology & Scope
For more information about this report visit https://www.researchandmarkets.com/r/rym7v0
